This content is for members only
This content is for members only
Glaukos subsequently advanced a second-generation treatment, Epioxa, through phase III trials. SanaCurrents assigns a pivolat probability Glaukos will submit an NDA for Epioxa in 2022.
This content is for members only
This content is for members only
This content is for members only
This content is for members only
This content is for members only